OncoRes Medical today announced it has closed an AUD $27M private funding round (‘the Funding round’) to progress clinical development and regulatory milestones for its Quantitative Micro-Elastography (QME) Imaging System, Elora™.
Read moreGeorge Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil
Read moreCUREator+ delivers $15.7 m to local BioMedTech Startups Tackling the Global Dementia Challenge
Read moreCUREator BioTech Incubator Grants $1.23M Top-Up Funding to High-Performing Participants
Read moreBrandon BioCatalyst’s CUREator set to support up to 15 therapeutic biotech’s thanks to funding from the Medical Research Future Fund.
Read morePolyActiva Secures $40M in Series C Financing to Advance PREZIA™ Platform Technology and Drive Innovation in Sustained Ocular Drug Delivery
Read moreVaxxas Secures New U.S. Patent For its Needle-Free Vaccination Manufacturing Technology
Read moreVaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery
Read moreENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051
Read moreVaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination
Read moreGeorge Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America
Read morePathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers
Read morePolyActiva Showcases Promising Clinical Data Highlighting its Polymer Technology’s Potential to Transform Glaucoma Care
Read morePhase III trial results of novel triple combination pill for hypertension published in The Lancet
Read moreBrandon BioCatalyst’s CUREator Incubator Boosts Preclinical and Health Security Biotech Innovations with $1.865m in funding.
Read moreENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral
Read moreENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051
Read moreFunding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential
Read moreAzura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
Read more$3 million in Funding to Support Early-Stage Biomedtech Projects Focused on Minimising Antimicrobial Resistance Thanks to the CSIRO
Read moreAravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
Read moreVaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa
Read moreCerta Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma
Read morePathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer
Read moreRecruitment completes for second Phase III hypertension trial investigating GMRx2 (George Medicines)
Read moreGlyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer
Read moreVaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine
Read moreEBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation
Read moreVaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP)
Read moreGround-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
Read moreEntact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement
Read moreVaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate
Read moreAzura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction
Read moreVaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)
Read morePathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022
Read moreOpinion: Taking the leap: transitioning from academia to industry – by Christina Kulis
Read moreAzura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction
Read moreAzura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)
Read moreGeorge Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial
Read more$16m cash injection to progress first-in-class therapy for inflammation and fibrosis
Read moreAustralian medical device company secures additional $12.5m to advance its breast cancer imaging system towards clinical trials
Read moreParkinson’s patients benefit from revolutionary watch on the NHS to manage care at home
Read moreAravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
Read moreClinical trial begins in the UK to investigate 3-in-1 high blood pressure pill
Read moreOpinion: It’s time to make our own supply of lifesaving drugs – Chris Nave
Read moreLife science researchers and entrepreneurs encouraged to seek investment from new $40m Australian biotech incubator
Read moreAustralia’s first national biotech incubator established with $40m MRFF investment
Read more‘No amount could be enough’: Calls for Canberra to back biotech, as medtech firms await funding
Read morePromising new potential treatment for leading cause of Dry Eye Disease a step closer as Azura Ophthalmics announces positive results in Phase 2 Program
Read moreOncoRes Medical receives $150,000 funding boost from Western Australian Government
Read moreMyricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer
Read moreVaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response
Read moreHarro Höfliger and Vaxxas Announce Alliance to Develop Industrial‐scale Aseptic Processing Line for Vaccine Products Based on Vaxxas’ High Density Microarray Patch (HD‐MAP)
Read moreQUE Oncology Appoints Dr. Julie Cherrington and Elizabeth Cermak to Board of Directors
Read moreMRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis
Read moreMRCF invests in San Diego ophthalmic biotech company, clinical trials to take place in Australia
Read moreAustralian biotech company launched with AU$7m investment to develop therapies for treating obesity
Read moreLevel 9, 31 Queen Street
Melbourne VIC 3000
Phone +61 3 9657 0700
Email: info@brandonbiocatalyst.com
Suite 2.05, 1 York Street
Sydney NSW 2000
Phone +61 2 8227 7080
Email: info@brandonbiocatalyst.com
